• Home
  • About Us
    • About Us
    • Leadership Team
  • Science
    • Biologics
    • Biomanufacturing
    • Pipeline
  • Investors
    • Overview
    • SEC Filings
    • Press Releases
    • Presentations
    • Corporate Governance
    • Investor Resources
      semaglutide
      • Email Alerts
      • FAQs
      • Tax Documents
  • Careers
  • Contact Us

Tivic Health: Christina Valauri Appointed to Board of Directors

Jun 18, 2024 | Press Releases

Wall Street Capital Markets Veteran and Recognized All-Star Bio-Medical Technology Analyst joins Tivic Health’s Governance Team SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops...

Tivic Health: Christina Valauri Appointed to Board of Directors

Jun 18, 2024 | Press Releases

Wall Street Capital Markets Veteran and Recognized All-Star Bio-Medical Technology Analyst joins Tivic Health’s Governance Team SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops...

Tivic Health Partners with the Feinstein Institutes to Advance its Patent-pending, Non-Invasive Cervical Vagus Nerve Stimulation; Begins Optimization of ncVNS for use in Clinical Indications

May 22, 2024 | Press Releases

SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today it has initiated the second phase of its clinical work to advance its...

Tivic Reports First Quarter 2024 Financial Results and Subsequent Events

May 15, 2024 | Press Releases

SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its first quarter 2024 financial results with discussion of subsequent events....

Tivic Health to Report Q1 2024 Financial Results and Subsequent Events on May 15th Via Conference Call and Webcast

May 13, 2024 | Press Releases

SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q1 2024 financial results via pre-recorded...

Tivic Health to Report Q1 2024 Financial Results and Subsequent Events on May 15th Via Conference Call and Webcast

May 13, 2024 | Press Releases

SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q1 2024 financial results via pre-recorded...
« Older Entries
Next Entries »

Recent Posts

  • Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
  • Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
  • Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird’s National Security Conference
  • Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
  • Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation

Recent Comments

No comments to show.
©2026 Valion Bio

Privacy Policy

For ClearUP customer questions regarding warranty or other device inquiries, please reach out to customerservice@tivichealth.com.